[
  {
    "ts": null,
    "headline": "Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays",
    "summary": "There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.",
    "url": "https://finnhub.io/api/news?id=155696520a1057b0caddf87645ef4729a6e38fc6f298b5bdaa5bb3feddc84e72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752168602,
      "headline": "Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays",
      "id": 135866756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.",
      "url": "https://finnhub.io/api/news?id=155696520a1057b0caddf87645ef4729a6e38fc6f298b5bdaa5bb3feddc84e72"
    }
  },
  {
    "ts": null,
    "headline": "European Equities Close Mostly Higher in Thursday Trading; EC President Survives No-Confidence Vote",
    "summary": "The European stock markets closed mostly higher in Thursday trading as The Stoxx Europe 600 rose 0.5",
    "url": "https://finnhub.io/api/news?id=e061e7d88f27d96d7ed2b2bae0e5dfdcdb6dc165977290468e5905b839453eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752163732,
      "headline": "European Equities Close Mostly Higher in Thursday Trading; EC President Survives No-Confidence Vote",
      "id": 135866758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The European stock markets closed mostly higher in Thursday trading as The Stoxx Europe 600 rose 0.5",
      "url": "https://finnhub.io/api/news?id=e061e7d88f27d96d7ed2b2bae0e5dfdcdb6dc165977290468e5905b839453eeb"
    }
  },
  {
    "ts": null,
    "headline": "Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 | Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways",
    "summary": "Danon disease, a rare X-linked dominant disorder due to LAMP2 gene mutations, primarily affects males, causing cardiomyopathy, skeletal myopathy, and cognitive issues. Advancements in NGS, whole exome/genome sequencing, and molecular diagnostics facilitate early, accurate detection. Gene therapies and clinical trials with orphan drug and fast track designations are revolutionizing treatment. Challenges include ultra-rare prevalence, high genetic therapy costs, and limited awareness. Yet, increas",
    "url": "https://finnhub.io/api/news?id=ba5b55c30ca8108e27b4d59082869a4cbb087091b6e5f9359690095d65861adb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752155700,
      "headline": "Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 | Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways",
      "id": 135853557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Danon disease, a rare X-linked dominant disorder due to LAMP2 gene mutations, primarily affects males, causing cardiomyopathy, skeletal myopathy, and cognitive issues. Advancements in NGS, whole exome/genome sequencing, and molecular diagnostics facilitate early, accurate detection. Gene therapies and clinical trials with orphan drug and fast track designations are revolutionizing treatment. Challenges include ultra-rare prevalence, high genetic therapy costs, and limited awareness. Yet, increas",
      "url": "https://finnhub.io/api/news?id=ba5b55c30ca8108e27b4d59082869a4cbb087091b6e5f9359690095d65861adb"
    }
  },
  {
    "ts": null,
    "headline": "Alcohol Related Liver Disease Market Forecast, 2025-2035 | Personalized Medicine Transforming ARLD Treatment Landscape",
    "summary": "The Global Alcohol-Related Liver Disease Market report for 2025-2035 highlights the escalating trend of alcohol-related liver conditions like alcoholic fatty liver disease (AFLD), alcoholic hepatitis, fibrosis, and cirrhosis, driven by rising alcohol consumption. Key players including Merck, Pfizer, and Novartis are innovating treatments and diagnostics to combat these diseases. Early detection advances and personalized medicine are boosting market growth. Despite challenges like late diagnosis",
    "url": "https://finnhub.io/api/news?id=fc574c7cf7eadc46a9410c55e36b866d579c7fb966dbf816ed8e4a52fd4fc525",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752155220,
      "headline": "Alcohol Related Liver Disease Market Forecast, 2025-2035 | Personalized Medicine Transforming ARLD Treatment Landscape",
      "id": 135855970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Alcohol-Related Liver Disease Market report for 2025-2035 highlights the escalating trend of alcohol-related liver conditions like alcoholic fatty liver disease (AFLD), alcoholic hepatitis, fibrosis, and cirrhosis, driven by rising alcohol consumption. Key players including Merck, Pfizer, and Novartis are innovating treatments and diagnostics to combat these diseases. Early detection advances and personalized medicine are boosting market growth. Despite challenges like late diagnosis",
      "url": "https://finnhub.io/api/news?id=fc574c7cf7eadc46a9410c55e36b866d579c7fb966dbf816ed8e4a52fd4fc525"
    }
  },
  {
    "ts": null,
    "headline": "XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence",
    "summary": "NEW YORK & TOKYO, July 10, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemica",
    "url": "https://finnhub.io/api/news?id=7a240bdfe992ad1601512dca55b9025d6fc96fed2bb99637b8489cc568975c02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752144300,
      "headline": "XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence",
      "id": 135849024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK & TOKYO, July 10, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemica",
      "url": "https://finnhub.io/api/news?id=7a240bdfe992ad1601512dca55b9025d6fc96fed2bb99637b8489cc568975c02"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI",
    "summary": "Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the Phase 3 EMBARK study evaluating XTANDI , in combination with leuprolide and as a...",
    "url": "https://finnhub.io/api/news?id=69d9564a09235367edd4d304aaa272b6caae644df8a45c9d535016f16781fee5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752143782,
      "headline": "Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI",
      "id": 135852955,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the Phase 3 EMBARK study evaluating XTANDI , in combination with leuprolide and as a...",
      "url": "https://finnhub.io/api/news?id=69d9564a09235367edd4d304aaa272b6caae644df8a45c9d535016f16781fee5"
    }
  },
  {
    "ts": null,
    "headline": "3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies",
    "summary": "I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. View the full analysis here.",
    "url": "https://finnhub.io/api/news?id=4342310aa20b4bea536434e9e6a6836406580eff81050f694d88d945eb8aacf4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752135424,
      "headline": "3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies",
      "id": 135849782,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/693468492/image_693468492.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. View the full analysis here.",
      "url": "https://finnhub.io/api/news?id=4342310aa20b4bea536434e9e6a6836406580eff81050f694d88d945eb8aacf4"
    }
  },
  {
    "ts": null,
    "headline": "Xtandi plus leuprolide significantly improves survival outcomes in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence",
    "summary": "Pfizer Inc: Xtandi plus leuprolide significantly improves survival outcomes in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence Pfizer: Embark met...",
    "url": "https://finnhub.io/api/news?id=a571888806ea05eea0b2ce0ac61737abb0e58199a9c679c23eb11e5f0f5b8120",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752130402,
      "headline": "Xtandi plus leuprolide significantly improves survival outcomes in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence",
      "id": 135847655,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc: Xtandi plus leuprolide significantly improves survival outcomes in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence Pfizer: Embark met...",
      "url": "https://finnhub.io/api/news?id=a571888806ea05eea0b2ce0ac61737abb0e58199a9c679c23eb11e5f0f5b8120"
    }
  },
  {
    "ts": null,
    "headline": "EU's von der Leyen survives parliament confidence vote",
    "summary": "European CommissionPresident Ursula von der Leyen survived a no-confidence vote inthe European Parliament on Thursday, tabled by mainly far-rightlawmakers who alleged she and her team undermined...",
    "url": "https://finnhub.io/api/news?id=b60bd268607b620ce63cc3298539dec5156447048953933884abcbcb13bf17d3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752129250,
      "headline": "EU's von der Leyen survives parliament confidence vote",
      "id": 135847278,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "European CommissionPresident Ursula von der Leyen survived a no-confidence vote inthe European Parliament on Thursday, tabled by mainly far-rightlawmakers who alleged she and her team undermined...",
      "url": "https://finnhub.io/api/news?id=b60bd268607b620ce63cc3298539dec5156447048953933884abcbcb13bf17d3"
    }
  }
]